JO
CRMD icon

John Overdeck’s CorMedix CRMD Stock Holding History

John Overdeck’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$321K Buy
40,859
+20,271
+98% +$160K ﹤0.01% 4479
2026
Q1 		$140K Sell
20,588
-160,518
-89% -$1.19M ﹤0.01% 4343
2025
Q4 		$2.11M Buy
181,106
+52,551
+41% +$581K ﹤0.01% 2399
2025
Q3 		$1.5M Sell
128,555
-188,408
-59% -$2.28M ﹤0.01% 2324
2025
Q2 		$3.9M Buy
316,963
+289,013
+1,034% +$3.19M 0.01% 1395
2025
Q1 		$172K Sell
27,950
-3,539
-11% -$36.6K ﹤0.01% 2883
2024
Q4 		$255K Buy
31,489
+5,189
+20% +$51.8K ﹤0.01% 2792
2024
Q3 		$213K Sell
26,300
-130,436
-83% -$706K ﹤0.01% 2788
2024
Q2 		$679K Buy
156,736
+93,751
+149% +$476K ﹤0.01% 2213
2024
Q1 		$267K Sell
62,985
-114,753
-65% -$398K ﹤0.01% 2606
2023
Q4 		$668K Sell
177,738
-50,871
-22% -$175K ﹤0.01% 2306
2023
Q3 		$846K Buy
228,609
+189,509
+485% +$754K ﹤0.01% 2029
2023
Q2 		$155K Sell
39,100
-55,781
-59% -$276K ﹤0.01% 2690
2023
Q1 		$393K Sell
94,881
-4,286
-4% -$17.5K ﹤0.01% 2310
2022
Q4 		$418K Sell
99,167
-18,111
-15% -$64.1K ﹤0.01% 2102
2022
Q3 		$332K Sell
117,278
-85,684
-42% -$356K ﹤0.01% 1930
2022
Q2 		$816K Buy
202,962
+131,036
+182% +$487K ﹤0.01% 1628
2022
Q1 		$394K Sell
71,926
-32,934
-31% -$151K ﹤0.01% 2125
2021
Q4 		$477K Sell
104,860
-24,398
-19% -$121K ﹤0.01% 3295
2021
Q3 		$601K Sell
129,258
-69,442
-35% -$404K ﹤0.01% 3077
2021
Q2 		$1.36M Buy
+198,700
New +$1.58M ﹤0.01% 2206
2021
Q1 		– Sell
-152,369
Closed -$1.13M – 3879
2020
Q4 		$1.13M Buy
152,369
+78,243
+106% +$532K ﹤0.01% 1892
2020
Q3 		$447K Buy
74,126
+19,800
+36% +$99.4K ﹤0.01% 2328
2020
Q2 		$342K Buy
+54,326
New +$252K ﹤0.01% 2287

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

John Overdeck's CRMD Position: Q2 2026 in Review

John Overdeck increased its CorMedix (CRMD) stake by 98% in Q2 2026, buying an estimated $160K and bringing the position to 40,859 shares worth $321K. The position accounts for ﹤0.01% of the portfolio, ranked #4479.

John Overdeck first reported a position in CRMD in Q2 2020 and has held it in 24 quarters since. The position peaked at $3.9M in Q2 2025. 192 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

  • John Overdeck held 40,859 shares of CorMedix worth $321K as of Q2 2026.
  • John Overdeck bought 20,271 CorMedix shares in Q2 2026, an estimated $160K.
  • CorMedix made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4479 holding.
  • John Overdeck first reported a position in CorMedix in Q2 2020 and has held it in 24 quarters since.
  • John Overdeck's CorMedix position peaked at $3.9M in Q2 2025.
  • 192 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.